Gilead notch­es an­oth­er Phase 3 win for Trodelvy in triple-neg­a­tive breast can­cer

Gilead’s Trodelvy has passed an­oth­er late-stage test in cer­tain pa­tients with metasta­t­ic triple-neg­a­tive breast can­cer (TNBC) — a win the com­pa­ny says could pave the way …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER